Abstract
Amiodarone therapy is widely prescribed in patients with atrial fibrillation. The higher prevalence of this arrhythmic heart disease, and the specific age-related issues of homeostasis in the elderly population, makes this group particularly exposed to its adverse effects. Among the many described side-effects, neurological impairments are the less documented and studied. Because amiodarone can be responsible for severe complications, as described in the case below, a close monitoring is necessary throughout its prescription. Awareness should be brought on the amiodarone-induced neurological side-effects as they could be overlooked.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ECS guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210
Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromuscul Dis. 2002 Mar; 3(3):97–105. https://doi.org/10.1097/00131402-200203000-00001
Agence Nationale de la Sécurité du Médicament et des produits de santé. Base de données publique des médicaments. Amiodarone — Résumé des caractéristiques du produit. 2020 update, http://base-donnees-publique.medicaments.gouv.fr
Pomponio G, Zurich MG, Schultz L, Weiss D, Romanelli L, Gramowski-Voss A et al. Amiodarone biokinetics, the formation of its major oxidative metabolite and neurotoxicity after acute and repeated exposure of brain cell cultures. Toxicology in vitro 2015; 30:192–202. https://doi.org/10.1016/j.tiv.2015.01.012
Hostetier KY, Giordano JR, Jellison EJ. In vitro inhibition of lysosomal phospholipase A, of rat lung by amiodarone and desethylamiodarone. BBA 1988; 959(3):316–321. https://doi.org/10.1016/0005-2760(88)90205-6
Orr CF, Ahlskog E. Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity. Arch Neurol 2009; 66(7):865–869. https://doi.org/10.1001/archneurol.2009.96
Chaubey VK, Chhabra L, Kapila A. Ataxia: a diagnostic perplexity and management dilemma. BMJ Case Rep 2013. https://doi.org/10.1136/bcr-2013-200575
Hindle JV, Irahim A, Ramaraj R. Ataxia caused by amiodarone in older people. Age and ageing 2008; 37:347–348. https://doi.org/10.1093/ageing/afn063
Krause DG, Segal AZ, Kligfield P. Severe ataxia caused by amiodarone. Am J Cardiol 2005; 96:1463–1464. https://doi.org/10.1016/j.amjcard.2005.06.093
Honegger UE, Scuntaro I, Wiesmann UN. Vitamine E reduces accumulation of amiodarone and desethylamiodarone and inhibits phospholipidosis in cultured human cells. Biochemical Pharmacology 1995; 49(12):1741–1745. https://doi.org/10.1016/0006-2952(95)00100-E
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest: The authors repport no conflicts of interest.
Rights and permissions
About this article
Cite this article
Sarrazin, S., Hein, C., Delrieu, J. et al. Amiodarone-induced Ataxia: A Case Report of Severe Cerebellar Dysfunction and Review of Literature. J Nutr Health Aging 25, 284–286 (2021). https://doi.org/10.1007/s12603-020-1475-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-020-1475-4